gi-102
Astrocytoma (Excluding Glioblastoma)
Explore 5 assets in Astrocytoma (Excluding Glioblastoma) →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07301268CT.gov GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Astrocytoma (Excluding Glioblastoma)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| gi-102 (this asset) | Mayo Clinic | P2 | CCC · 53 |
| Niraparib | University of Oklahoma | P2 | CCC |
| Pembrolizumab | Mayo Clinic | P2 | CCC |
| Eras-801 | Jonsson Comprehensive Cancer Center | P1 | CC |
| Fludeoxyglucose | Jonsson Comprehensive Cancer Center | P1 | CC |
Other indications for gi-102
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Astrocytoma, IDH-Mutant, Grade 4 | — | P2 | CCC · 53 |
| IDH-Wildtype Glioblastoma | — | P2 | CCC · 53 |
| Glioblastoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. gi-102 in Astrocytoma (Excluding Glioblastoma). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gi-102-astrocytoma-excluding-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →